Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 10c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.53), $0.10 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hub Group faces credibility test as Q2 report looms Sept. 1
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst